AI helped map brown fat in thousands of scans. The drug clue is not a cure.

An existing blood-pressure medicine has become an intriguing candidate in brown-fat research, but the evidence has not crossed into a human treatment claim. In a peer-reviewed Nature study, researchers analyzed imaging and records from 101,243 patients at a large cancer center. Brown fat, which spends energy producing heat, was associated with lower prevalence of several cardiovascular and psychiatric diagnoses. Machine learning allowed the team to semi-automatically quantify brown-fat activity in roughly 8,700 patients. Higher activity, particularly in one underarm depot, correlated with lower odds of cardiometabolic disease and a healthier distribution of white fat. Medication records then pointed to a class of blood-pressure drugs. Follow-up tests found that losartan increased brown-fat cell activity and energy expenditure in mice. That sequence matters: the AI analysis helped move from a broad clinical pattern to a specific, experimentally testable mechanism. It also sets a firm boundary. These patients were not randomized to change brown-fat activity; they were drawn from a cancer center; and the losartan result was not a trial showing improved human outcomes. The NIH describes it as a possible route to future drug repurposing, not a current indication. Patients should not alter medication because of a headline. The next evidence should be replication in other populations and prospective testing that measures patient outcomes, dosage and adverse effects. The real success of AI here is accelerating a scientific question without pretending the answer is finished.